Advertisement
Review Article| Volume 37, ISSUE 4, P697-723, December 2017

Flow Cytometry of B-Cell Neoplasms

Published:August 30, 2017DOI:https://doi.org/10.1016/j.cll.2017.07.001

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Clinics in Laboratory Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Chen H.I.
        • Akpolat I.
        • Mody D.R.
        • et al.
        Restricted kappa/lambda light chain ratio by flow cytometry in germinal center B cells in Hashimoto thyroiditis.
        Am J Clin Pathol. 2006; 125: 42-48
        • Chizuka A.
        • Kanda Y.
        • Nannya Y.
        • et al.
        The diagnostic value of kappa/lambda ratios determined by flow cytometric analysis of biopsy specimens in B-cell lymphoma.
        Clin Lab Haematol. 2002; 24: 33-36
        • Reichard K.K.
        • McKenna R.W.
        • Kroft S.H.
        Comparative analysis of light chain expression in germinal center cells and mantle cells of reactive lymphoid tissues. A four-color flow cytometric study.
        Am J Clin Pathol. 2003; 119: 130-136
        • Geary W.A.
        • Frierson H.F.
        • Innes D.J.
        • et al.
        Quantitative criteria for clonality in the diagnosis of B-cell non- Hodgkin's lymphoma by flow cytometry.
        Mod Pathol. 1993; 6: 155-161
        • Taylor C.R.
        Results of multiparameter studies of B-cell lymphomas.
        Am J Clin Pathol. 1979; 72: 687-698
        • Ray S.
        • Craig F.E.
        • Swerdlow S.H.
        Abnormal patterns of antigenic expression in follicular lymphoma: a flow cytometric study.
        Am J Clin Pathol. 2005; 124: 576-583
        • Huang J.
        • Fan G.
        • Zhong Y.
        • et al.
        Diagnostic usefulness of aberrant CD22 expression in differentiating neoplastic cells of B-Cell chronic lymphoproliferative disorders from admixed benign B cells in four-color multiparameter flow cytometry.
        Am J Clin Pathol. 2005; 123: 826-832
        • Sanchez M.L.
        • Almeida J.
        • Vidriales B.
        • et al.
        Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation.
        Leukemia. 2002; 16: 1460-1469
        • Yang W.
        • Agrawal N.
        • Patel J.
        • et al.
        Diminished expression of CD19 in B-cell lymphomas.
        Cytometry B Clin Cytom. 2005; 63: 28-35
        • Reichard K.K.
        • Kroft S.H.
        Flow cytometry in the assessment of hematologic disorders.
        in: Orazi A. Foucar K. Knowles D.M. Neoplastic hematopathology. Lippincott, Williams and Wilkins, Baltimore (MD)2013: 119-145
        • Kussick S.J.
        • Kalnoski M.
        • Braziel R.M.
        • et al.
        Prominent clonal B cell populations identified by flow cytometry in histologically-reactive lymphoid proliferations.
        Am J Clin Pathol. 2004; 121: 464-472
        • Kroft S.H.
        Monoclones, monotypes, and neoplasia pitfalls in lymphoma diagnosis.
        Am J Clin Pathol. 2004; 121: 457-459
        • Zhao X.F.
        • Cherian S.
        • Sargent R.
        • et al.
        Expanded populations of surface membrane immunoglobulin light chain-negative B cells in lymph nodes are not always indicative of B-cell lymphoma.
        Am J Clin Pathol. 2005; 124: 143-150
        • Li S.
        • Eshleman J.R.
        • Borowitz M.J.
        Lack of surface immunoglobulin light chain expression by flow cytometric immunophenotyping can help diagnose peripheral B-cell lymphoma.
        Am J Clin Pathol. 2002; 118: 229-234
        • Horna P.
        • Olteanu H.
        • Kroft S.H.
        • et al.
        Flow cytometric analysis of surface light chain expression patterns in B-cell lymphomas using monoclonal and polyclonal antibodies.
        Am J Clin Pathol. 2011; 136: 954-959
        • Kesler M.V.
        • Paranjape G.S.
        • Asplund S.L.
        • et al.
        Anaplastic large cell lymphoma: a flow cytometric analysis of 29 cases.
        Am J Clin Pathol. 2007; 128: 314-322
        • Xu Y.
        • McKenna R.W.
        • Kroft S.H.
        Assessment of CD10 in the diagnosis of small B-cell lymphomas: a multiparameter flow cytometric study.
        Am J Clin Pathol. 2002; 117: 291-300
        • Matutes E.
        • Owusu-Ankomah K.
        • Morilla R.
        • et al.
        The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL.
        Leukemia. 1994; 8: 1640-1645
        • Almasri N.M.
        • Duque R.E.
        • Iturraspe J.
        • et al.
        Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia.
        Am J Hematol. 1992; 40: 259-263
        • Moreau E.J.
        • Matutes E.
        • A'Hern R.P.
        • et al.
        Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b).
        Am J Clin Pathol. 1997; 108: 378-382
        • Baseggio L.
        • Traverse-Glehen A.
        • Petinataud F.
        • et al.
        CD5 expression identifies a subset of splenic marginal zone lymphomas with higher lymphocytosis: a clinico-pathological, cytogenetic and molecular study of 24 cases.
        Haematologica. 2010; 95: 604-612
        • Ballesteros E.
        • Osborne B.M.
        • Matsushima A.Y.
        CD5+ low-grade marginal zone B-cell lymphomas with localized presentation.
        Am J Surg Pathol. 1998; 22: 201-207
        • Ferry J.A.
        • Yang W.I.
        • Zukerberg L.R.
        • et al.
        CD5+ extranodal marginal zone B-cell (MALT) lymphoma. A low grade neoplasm with a propensity for bone marrow involvement and relapse.
        Am J Clin Pathol. 1996; 105: 31-37
        • Dronca R.S.
        • Jevremovic D.
        • Hanson C.A.
        • et al.
        CD5-positive chronic B-cell lymphoproliferative disorders: diagnosis and prognosis of a heterogeneous disease entity.
        Cytometry B Clin Cytom. 2010; 78: S35-S41
        • Morice W.G.
        • Chen D.
        • Kurtin P.J.
        • et al.
        Novel immunophenotypic features of marrow lymphoplasmacytic lymphoma and correlation with Waldenstrom's macroglobulinemia.
        Mod Pathol. 2009; 22: 807-816
        • Li Y.
        • Hu S.
        • Zuo Z.
        • et al.
        CD5-positive follicular lymphoma: clinicopathologic correlations and outcome in 88 cases.
        Mod Pathol. 2015; 28: 787-798
        • Jain D.
        • Dorwal P.
        • Gajendra S.
        • et al.
        CD5 positive hairy cell leukemia: a rare case report with brief review of literature.
        Cytometry B Clin Cytom. 2016; 90: 467-472
        • Konoplev S.
        • Medeiros L.J.
        • Bueso-Ramos C.E.
        • et al.
        Immunophenotypic profile of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia.
        Am J Clin Pathol. 2005; 124: 414-420
        • Dong H.Y.
        • Gorczyca W.
        • Liu Z.
        • et al.
        B-cell lymphomas with coexpression of CD5 and CD10.
        Am J Clin Pathol. 2003; 119: 218-230
        • Kilo M.N.
        • Dorfman D.M.
        The utility of flow cytometric immunophenotypic analysis in the distinction of small lymphocytic lymphoma/chronic lymphocytic leukemia from mantle cell lymphoma.
        Am J Clin Pathol. 1996; 105: 451-457
        • Huh Y.O.
        • Pugh W.C.
        • Kantarjian H.M.
        • et al.
        Detection of subgroups of chronic B-cell leukemias by FMC7 monoclonal antibody.
        Am J Clin Pathol. 1994; 101: 283-289
        • Molot R.J.
        • Meeker T.C.
        • Wittwer C.T.
        • et al.
        Antigen expression and polymerase chain reaction amplification of mantle cell lymphomas.
        Blood. 1994; 83: 1626-1631
        • Zukerberg L.R.
        • Medeiros L.J.
        • Ferry J.A.
        • et al.
        Diffuse low-grade B-cell lymphomas. Four clinically distinct subtypes defined by a combination of morphologic and immunophenotypic features.
        Am J Clin Pathol. 1993; 100: 373-385
        • Argatoff L.H.
        • Connors J.M.
        • Klasa R.J.
        • et al.
        Mantle cell lymphoma: a clinicopathologic study of 80 cases.
        Blood. 1997; 89: 2067-2078
        • Asplund S.L.
        • McKenna R.W.
        • Doolittle J.E.
        • et al.
        CD5-positive B-cell neoplasms of indeterminate immunophenotype: a clinicopathologic analysis of 26 cases.
        Appl Immunohistochem Mol Morphol. 2005; 13: 311-317
        • Schlette E.
        • Fu K.
        • Medeiros L.J.
        CD23 expression in mantle cell lymphoma: clinicopathologic features of 18 cases.
        Am J Clin Pathol. 2003; 120: 760-766
        • Dorfman D.M.
        • Pinkus G.S.
        Distinction between small lymphocytic and mantle cell lymphoma by immunoreactivity for CD23.
        Mod Pathol. 1994; 7: 326-331
        • Gong J.Z.
        • Lagoo A.S.
        • Peters D.
        • et al.
        Value of CD23 determination by flow cytometry in differentiating mantle cell lymphoma from chronic lymphocytic leukemia/small lymphocytic lymphoma.
        Am J Clin Pathol. 2001; 116: 893-897
        • Palumbo G.A.
        • Parrinello N.
        • Fargione G.
        • et al.
        CD200 expression may help in differential diagnosis between mantle cell lymphoma and B-cell chronic lymphocytic leukemia.
        Leuk Res. 2009; 33: 1212-1216
        • Kelemen K.
        • Peterson L.C.
        • Helenowski I.
        • et al.
        CD23+ mantle cell lymphoma: a clinical pathologic entity associated with superior outcome compared with CD23- disease.
        Am J Clin Pathol. 2008; 130: 166-177
        • Gao J.
        • Peterson L.
        • Nelson B.
        • et al.
        Immunophenotypic variations in mantle cell lymphoma.
        Am J Clin Pathol. 2009; 132: 699-706
        • Challagundla P.
        • Medeiros L.J.
        • Kanagal-Shamanna R.
        • et al.
        Differential expression of CD200 in B-cell neoplasms by flow cytometry can assist in diagnosis, subclassification, and bone marrow staging.
        Am J Clin Pathol. 2014; 142: 837-844
        • Sandes A.F.
        • de Lourdes Chauffaille M.
        • Oliveira C.R.
        • et al.
        CD200 has an important role in the differential diagnosis of mature B-cell neoplasms by multiparameter flow cytometry.
        Cytometry B Clin Cytom. 2014; 86: 98-105
        • Alapat D.
        • Coviello-Malle J.
        • Owens R.
        • et al.
        Diagnostic usefulness and prognostic impact of CD200 expression in lymphoid malignancies and plasma cell myeloma.
        Am J Clin Pathol. 2012; 137: 93-100
        • Fan L.
        • Miao Y.
        • Wu Y.J.
        • et al.
        Expression patterns of CD200 and CD148 in leukemic B-cell chronic lymphoproliferative disorders and their potential value in differential diagnosis.
        Leuk Lymphoma. 2015; 56: 3329-3335
        • Challagundla P.
        • Jorgensen J.L.
        • Kanagal-Shamanna R.
        • et al.
        Utility of quantitative flow cytometry immunophenotypic analysis of CD5 expression in small B-cell neoplasms.
        Arch Pathol Lab Med. 2014; 138: 903-909
        • Kraus T.S.
        • Sillings C.N.
        • Saxe D.F.
        • et al.
        The role of CD11c expression in the diagnosis of mantle cell lymphoma.
        Am J Clin Pathol. 2010; 134: 271-277
        • Tiacci E.
        • Trifonov V.
        • Schiavoni G.
        • et al.
        BRAF mutations in hairy-cell leukemia.
        N Engl J Med. 2011; 364: 2305-2315
        • Tiacci E.
        • Schiavoni G.
        • Forconi F.
        • et al.
        Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation.
        Blood. 2012; 119: 192-195
        • Arcaini L.
        • Zibellini S.
        • Boveri E.
        • et al.
        The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms.
        Blood. 2012; 119: 188-191
        • Else M.
        • Dearden C.E.
        • Matutes E.
        • et al.
        Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis.
        Br J Haematol. 2009; 145: 733-740
        • Robbins B.A.
        • Ellison D.J.
        • Spinosa J.C.
        • et al.
        Diagnostic application of two-color flow cytometry in 161 cases of hairy cell leukemia.
        Blood. 1993; 82: 1277-1287
        • Venkataraman G.
        • Aguhar C.
        • Kreitman R.J.
        • et al.
        Characteristic CD103 and CD123 expression pattern defines hairy cell leukemia: usefulness of CD123 and CD103 in the diagnosis of mature B-cell lymphoproliferative disorders.
        Am J Clin Pathol. 2011; 136: 625-630
        • Del Giudice I.
        • Matutes E.
        • Morilla R.
        • et al.
        The diagnostic value of CD123 in B-cell disorders with hairy or villous lymphocytes.
        Haematologica. 2004; 89: 303-308
        • Pillai V.
        • Pozdnyakova O.
        • Charest K.
        • et al.
        CD200 flow cytometric assessment and semiquantitative immunohistochemical staining distinguishes hairy cell leukemia from hairy cell leukemia-variant and other B-cell lymphoproliferative disorders.
        Am J Clin Pathol. 2013; 140: 536-543
        • Matutes E.
        • Morilla R.
        • Owusu-Ankomah K.
        • et al.
        The immunophenotype of hairy cell leukemia (HCL). Proposal for a scoring system to distinguish HCL from B-cell disorders with hairy or villous lymphocytes.
        Leuk Lymphoma. 1994; 14: 57-61
        • Chen Y.H.
        • Tallman M.S.
        • Goolsby C.
        • et al.
        Immunophenotypic variations in hairy cell leukemia.
        Am J Clin Pathol. 2006; 125: 251-259
        • Jasionowski T.M.
        • Hartung L.
        • Greenwood J.H.
        • et al.
        Analysis of CD10+ hairy cell leukemia.
        Am J Clin Pathol. 2003; 120: 228-235
        • Chen D.
        • Morice W.G.
        • Viswanatha D.S.
        • et al.
        CD5-positive hairy cell leukemia: a rare but distinct variant.
        Mod Pathol. 2009; 22: 258A
        • Dong H.Y.
        • Weisberger J.
        • Liu Z.
        • et al.
        Immunophenotypic analysis of CD103+ B-lymphoproliferative disorders: hairy cell leukemia and its mimics.
        Am J Clin Pathol. 2009; 131: 586-595
        • Swerdlow S.H.
        • Campo E.
        • Pileri S.A.
        • et al.
        The 2016 revision of the World Health Organization classification of lymphoid neoplasms.
        Blood. 2016; 127: 2375-2390
        • Traverse-Glehen A.
        • Baseggio L.
        • Callet-Bauchu E.
        • et al.
        Hairy cell leukaemia-variant and splenic red pulp lymphoma: a single entity?.
        Br J Haematol. 2010; 150: 113-116
        • Cessna M.H.
        • Hartung L.
        • Tripp S.
        • et al.
        Hairy cell leukemia variant: fact or fiction.
        Am J Clin Pathol. 2005; 123: 132-138
        • Matutes E.
        • Wotherspoon A.
        • Brito-Babapulle V.
        • et al.
        The natural history and clinico-pathological features of the variant form of hairy cell leukemia.
        Leukemia. 2001; 15: 184-186
        • Sainati L.
        • Matutes E.
        • Mulligan S.
        • et al.
        A variant form of hairy cell leukemia resistant to alpha-interferon: clinical and phenotypic characteristics of 17 patients.
        Blood. 1990; 76: 157-162
        • de Totero D.
        • Tazzari P.L.
        • Lauria F.
        • et al.
        Phenotypic analysis of hairy cell leukemia: “variant” cases express the interleukin-2 receptor beta chain, but not the alpha chain (CD25).
        Blood. 1993; 82: 528-535
        • Baseggio L.
        • Traverse-Glehen A.
        • Callet-Bauchu E.
        • et al.
        Relevance of a scoring system including CD11c expression in the identification of splenic diffuse red pulp small B-cell lymphoma (SRPL).
        Hematol Oncol. 2011; 29: 47-51
        • Traverse-Glehen A.
        • Baseggio L.
        • Bauchu E.C.
        • et al.
        Splenic red pulp lymphoma with numerous basophilic villous lymphocytes: a distinct clinicopathologic and molecular entity?.
        Blood. 2008; 111: 2253-2260
        • Kaleem Z.
        • White G.
        • Vollmer R.T.
        Critical analysis and diagnostic usefulness of limited immunophenotyping of B-cell non-Hodgkin lymphomas by flow cytometry.
        Am J Clin Pathol. 2001; 115: 136-142
        • Almasri N.M.
        • Iturraspe J.A.
        • Braylan R.C.
        CD10 expression in follicular lymphoma and large cell lymphoma is different from that of reactive lymph node follicles.
        Arch Pathol Lab Med. 1998; 122: 539-544
        • Kurtin P.J.
        • Hobday K.S.
        • Ziesmer S.
        • et al.
        Demonstration of distinct antigenic profiles of small B-cell lymphomas by paraffin section immunohistochemistry.
        Am J Clin Pathol. 1999; 112: 319-329
        • Zanetto U.
        • Dong H.
        • Huang Y.
        • et al.
        Mantle cell lymphoma with aberrant expression of CD10.
        Histopathology. 2008; 53: 20-29
        • Liu Z.
        • Dong H.Y.
        • Gorczyca W.
        • et al.
        CD5- mantle cell lymphoma.
        Am J Clin Pathol. 2002; 118: 216-224
        • Huang J.C.
        • Finn W.G.
        • Goolsby C.L.
        • et al.
        CD5- small B-cell leukemias are rarely classifiable as chronic lymphocytic leukemia.
        Am J Clin Pathol. 1999; 111: 123-130
        • Xu Y.
        • McKenna R.W.
        • Asplund S.L.
        • et al.
        Comparison of immunophenotypes of small B-cell neoplasms in primary lymph node and concurrent blood or marrow samples.
        Am J Clin Pathol. 2002; 118: 758-764
        • Onciu M.
        • Berrak S.G.
        • Medeiros L.J.
        • et al.
        Discrepancies in the immunophenotype of lymphoma cells in samples obtained simultaneously from different anatomic sites.
        Am J Clin Pathol. 2002; 117: 644-650
        • Echeverri C.
        • Fisher S.
        • King D.
        • et al.
        Immunophenotypic variability of B-cell non-Hodgkin lymphoma: a retrospective study of cases analyzed by flow cytometry.
        Am J Clin Pathol. 2002; 117: 615-620
        • Hamblin T.J.
        • Davis Z.
        • Gardiner A.
        • et al.
        Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.
        Blood. 1999; 94: 1848-1854
        • Damle R.N.
        • Wasil T.
        • Fais F.
        • et al.
        Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.
        Blood. 1999; 94: 1840-1847
        • Hamblin T.J.
        • Orchard J.A.
        • Ibbotson R.E.
        • et al.
        CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease.
        Blood. 2002; 99: 1023-1029
        • Oscier D.G.
        • Gardiner A.C.
        • Mould S.J.
        • et al.
        Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors.
        Blood. 2002; 100: 1177-1184
        • Jelinek D.F.
        • Tschumper R.C.
        • Geyer S.M.
        • et al.
        Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia.
        Br J Haematol. 2001; 115: 854-861
        • Ghia P.
        • Guida G.
        • Stella S.
        • et al.
        The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression.
        Blood. 2003; 101: 1262-1269
        • Krober A.
        • Seiler T.
        • Benner A.
        • et al.
        V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia.
        Blood. 2002; 100: 1410-1416
        • Ibrahim S.
        • Keating M.
        • Do K.A.
        • et al.
        CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia.
        Blood. 2001; 98: 181-186
        • Rassenti L.Z.
        • Jain S.
        • Keating M.J.
        • et al.
        Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia.
        Blood. 2008; 112: 1923-1930
        • Durig J.
        • Naschar M.
        • Schmucker U.
        • et al.
        CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia.
        Leukemia. 2002; 16: 30-35
        • Schroers R.
        • Griesinger F.
        • Trumper L.
        • et al.
        Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia.
        Leukemia. 2005; 19: 750-758
        • Boonstra J.G.
        • van Lom K.
        • Langerak A.W.
        • et al.
        CD38 as a prognostic factor in B cell chronic lymphocytic leukaemia (B-CLL): comparison of three approaches to analyze its expression.
        Cytometry B Clin Cytom. 2006; 70: 136-141
        • Mainou-Fowler T.
        • Dignum H.
        • Taylor P.R.
        • et al.
        Quantification improves the prognostic value of CD38 expression in B-cell chronic lymphocytic leukaemia.
        Br J Haematol. 2002; 118: 755-761
        • Thornton P.D.
        • Fernandez C.
        • Giustolisi G.M.
        • et al.
        CD38 expression as a prognostic indicator in chronic lymphocytic leukaemia.
        Hematol J. 2004; 5: 145-151
        • Del Giudice I.
        • Morilla A.
        • Osuji N.
        • et al.
        Zeta-chain associated protein 70 and CD38 combined predict the time to first treatment in patients with chronic lymphocytic leukemia.
        Cancer. 2005; 104: 2124-2132
        • Chevallier P.
        • Penther D.
        • Avet-Loiseau H.
        • et al.
        CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukaemia.
        Br J Haematol. 2002; 116: 142-150
        • Patten P.E.
        • Buggins A.G.
        • Richards J.
        • et al.
        CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment.
        Blood. 2008; 111: 5173-5181
        • Rosenwald A.
        • Alizadeh A.A.
        • Widhopf G.
        • et al.
        Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia.
        J Exp Med. 2001; 194: 1639-1647
        • Crespo M.
        • Bosch F.
        • Villamor N.
        • et al.
        ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.
        N Engl J Med. 2003; 348: 1764-1775
        • Wiestner A.
        • Rosenwald A.
        • Barry T.S.
        • et al.
        ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile.
        Blood. 2003; 101: 4944-4951
        • Orchard J.A.
        • Ibbotson R.E.
        • Davis Z.
        • et al.
        ZAP-70 expression and prognosis in chronic lymphocytic leukaemia.
        Lancet. 2004; 363: 105-111
        • Hassanein N.M.
        • Perkinson K.R.
        • Alcancia F.
        • et al.
        A single tube, four-color flow cytometry assay for evaluation of ZAP-70 and CD38 expression in chronic lymphocytic leukemia.
        Am J Clin Pathol. 2010; 133: 708-717
        • Rassenti L.Z.
        • Huynh L.
        • Toy T.L.
        • et al.
        ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia.
        N Engl J Med. 2004; 351: 893-901
        • Durig J.
        • Nuckel H.
        • Cremer M.
        • et al.
        ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia.
        Leukemia. 2003; 17: 2426-2434
        • Slack G.W.
        • Wizniak J.
        • Dabbagh L.
        • et al.
        Flow cytometric detection of ZAP-70 in chronic lymphocytic leukemia: correlation with immunocytochemistry and Western blot analysis.
        Arch Pathol Lab Med. 2007; 131: 50-56
        • Chen Y.H.
        • Peterson L.C.
        • Dittmann D.
        • et al.
        Comparative analysis of flow cytometric techniques in assessment of ZAP-70 expression in relation to IgVH mutational status in chronic lymphocytic leukemia.
        Am J Clin Pathol. 2007; 127: 182-191
        • Gibbs G.
        • Bromidge T.
        • Howe D.
        • et al.
        Comparison of flow cytometric methods for the measurement of ZAP-70 expression in a routine diagnostic laboratory.
        Clin Lab Haematol. 2005; 27: 258-266
        • Zucchetto A.
        • Bomben R.
        • Bo M.D.
        • et al.
        ZAP-70 expression in B-cell chronic lymphocytic leukemia: evaluation by external (isotypic) or internal (T/NK cells) controls and correlation with IgV(H) mutations.
        Cytometry B Clin Cytom. 2006; 70: 284-292
        • Wilhelm C.
        • Neubauer A.
        • Brendel C.
        Discordant results of flow cytometric ZAP-70 expression status in B-CLL samples if different gating strategies are applied.
        Cytometry B Clin Cytom. 2006; 70: 242-250
        • Shults K.E.
        • Miller D.T.
        • Davis B.H.
        • et al.
        A standardized ZAP-70 assay–lessons learned in the trenches.
        Cytometry B Clin Cytom. 2006; 70: 276-283
        • Letestu R.
        • Rawstron A.
        • Ghia P.
        • et al.
        Evaluation of ZAP-70 expression by flow cytometry in chronic lymphocytic leukemia: a multicentric international harmonization process.
        Cytometry B Clin Cytom. 2006; 70: 309-314
        • Bakke A.C.
        • Purtzer Z.
        • Leis J.
        • et al.
        A robust ratio metric method for analysis of Zap-70 expression in chronic lymphocytic leukemia (CLL).
        Cytometry B Clin Cytom. 2006; 70: 227-234
        • Best O.G.
        • Ibbotson R.E.
        • Parker A.E.
        • et al.
        ZAP-70 by flow cytometry: a comparison of different antibodies, anticoagulants, and methods of analysis.
        Cytometry B Clin Cytom. 2006; 70: 235-241
        • Sheikholeslami M.R.
        • Jilani I.
        • Keating M.
        • et al.
        Variations in the detection of ZAP-70 in chronic lymphocytic leukemia: comparison with IgV(H) mutation analysis.
        Cytometry B Clin Cytom. 2006; 70: 270-275
        • Gattei V.
        • Bulian P.
        • Del Principe M.I.
        • et al.
        Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia.
        Blood. 2008; 111: 865-873
        • Rossi D.
        • Cerri M.
        • Capello D.
        • et al.
        Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome.
        Br J Haematol. 2008; 142: 202-215
        • Baumann T.
        • Delgado J.
        • Santacruz R.
        • et al.
        CD49d (ITGA4) expression is a predictor of time to first treatment in patients with chronic lymphocytic leukaemia and mutated IGHV status.
        Br J Haematol. 2016; 172: 48-55
        • Dal Bo M.
        • Bulian P.
        • Bomben R.
        • et al.
        CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia.
        Leukemia. 2016; 30: 2011-2018
        • Shanafelt T.D.
        • Geyer S.M.
        • Bone N.D.
        • et al.
        CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential.
        Br J Haematol. 2008; 140: 537-546
        • Gooden C.E.
        • Jones P.
        • Bates R.
        • et al.
        CD49d shows superior performance characteristics for flow cytometric prognostic testing in chronic lymphocytic leukemia/small lymphocytic lymphoma.
        Cytometry B Clin Cytom. 2016; ([Epub ahead of print])
        • Zucchetto A.
        • Bomben R.
        • Dal Bo M.
        • et al.
        CD49d in B-cell chronic lymphocytic leukemia: correlated expression with CD38 and prognostic relevance.
        Leukemia. 2006; 20 ([author reply: 528–9]): 523-525
        • Olteanu H.
        • Fenske T.S.
        • Harrington A.M.
        • et al.
        CD23 expression in follicular lymphoma: clinicopathologic correlations.
        Am J Clin Pathol. 2011; 135: 46-53
        • Poret N.
        • Fu Q.
        • Guihard S.
        • et al.
        CD38 in hairy cell leukemia is a marker of poor prognosis and a new target for therapy.
        Cancer Res. 2015; 75: 3902-3911
        • Rawstron A.C.
        • Bottcher S.
        • Letestu R.
        • et al.
        Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL.
        Leukemia. 2013; 27: 142-149
        • Strati P.
        • Keating M.J.
        • O'Brien S.M.
        • et al.
        Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL.
        Blood. 2014; 123: 3727-3732
        • Sausville J.E.
        • Salloum R.G.
        • Sorbara L.
        • et al.
        Minimal residual disease detection in hairy cell leukemia. Comparison of flow cytometric immunophenotyping with clonal analysis using consensus primer polymerase chain reaction for the heavy chain gene.
        Am J Clin Pathol. 2003; 119: 213-217
        • Cheminant M.
        • Derrieux C.
        • Touzart A.
        • et al.
        Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study.
        Haematologica. 2016; 101: 336-345
        • Ladetto M.
        • Lobetti-Bodoni C.
        • Mantoan B.
        • et al.
        Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program.
        Blood. 2013; 122: 3759-3766
        • Sanchez M.L.
        • Almeida J.
        • Gonzalez D.
        • et al.
        Incidence and clinicobiologic characteristics of leukemic B-cell chronic lymphoproliferative disorders with more than one B-cell clone.
        Blood. 2003; 102: 2994-3002
        • Bertram H.C.
        • Check I.J.
        • Milano M.A.
        Immunophenotyping large B-cell lymphomas. Flow cytometric pitfalls and pathologic correlation.
        Am J Clin Pathol. 2001; 116: 191-203
        • Harrington A.M.
        • Olteanu H.
        • Kroft S.H.
        Most diffuse large B-cell lymphomas are identified by flow cytometry.
        Mod Pathol. 2012; 24: 339A
        • Johnson N.A.
        • Boyle M.
        • Bashashati A.
        • et al.
        Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival.
        Blood. 2009; 113: 3773-3780
        • Tomita N.
        • Takeuchi K.
        • Hyo R.
        • et al.
        Diffuse large B cell lymphoma without immunoglobulin light chain restriction by flow cytometry.
        Acta Haematol. 2009; 121: 196-201
        • Sorigue M.
        • Junca J.
        • Granada I.
        CD200 in high-grade lymphoma, chronic lymphocytic leukemia, and chronic lymphocytic leukemia-phenotype monoclonal B-cell lymphocytosis.
        Am J Clin Pathol. 2015; 144: 677-679
      1. Swerdlow S.H. Campo E. Harris N.L. WHO classification of tumors of haematopoietic and lymphoid tissues. IARC, Lyon (France)2008
        • Hans C.P.
        • Weisenburger D.D.
        • Greiner T.C.
        • et al.
        Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.
        Blood. 2004; 103: 275-282
        • Xu Y.
        • McKenna R.W.
        • Kroft S.H.
        Comparison of multiparameter flow cytometry with cluster analysis and immunohistochemistry for the detection of CD10 in diffuse large B-cell lymphomas.
        Mod Pathol. 2002; 15: 413-419
        • Yamaguchi M.
        • Seto M.
        • Okamoto M.
        • et al.
        De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients.
        Blood. 2002; 99: 815-821
        • Kroft S.H.
        • Dawson D.B.
        • McKenna R.W.
        Large cell lymphoma transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma. A flow cytometric analysis of seven cases.
        Am J Clin Pathol. 2001; 115: 385-395
        • Schniederjan S.D.
        • Li S.
        • Saxe D.F.
        • et al.
        A novel flow cytometric antibody panel for distinguishing Burkitt lymphoma from CD10+ diffuse large B-cell lymphoma.
        Am J Clin Pathol. 2010; 133: 718-726
        • McGowan P.
        • Nelles N.
        • Wimmer J.
        • et al.
        Differentiating between Burkitt lymphoma and CD10+ diffuse large B-cell lymphoma: the role of commonly used flow cytometry cell markers and the application of a multiparameter scoring system.
        Am J Clin Pathol. 2012; 137: 665-670
        • Maleki A.
        • Seegmiller A.C.
        • Uddin N.
        • et al.
        Bright CD38 expression is an indicator of MYC rearrangement.
        Leuk Lymphoma. 2009; 50: 1054-1057
        • Kesler M.V.
        • Xu Y.
        • Karandikar N.J.
        • et al.
        Flow cytometric comparison of Burkitt and CD10(+) large B-cell lymphomas [Abstract].
        Mod Pathol. 2005; 18: 237A
        • Horn H.
        • Ziepert M.
        • Becher C.
        • et al.
        MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma.
        Blood. 2013; 121: 2253-2263
        • Johnson N.A.
        • Savage K.J.
        • Ludkovski O.
        • et al.
        Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival.
        Blood. 2009; 114: 2273-2279
        • Le Gouill S.
        • Talmant P.
        • Touzeau C.
        • et al.
        The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement.
        Haematologica. 2007; 92: 1335-1342
        • Tomita N.
        • Tokunaka M.
        • Nakamura N.
        • et al.
        Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations.
        Haematologica. 2009; 94: 935-943
        • Kanungo A.
        • Medeiros L.J.
        • Abruzzo L.V.
        • et al.
        Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis.
        Mod Pathol. 2006; 19: 25-33
        • Snuderl M.
        • Kolman O.K.
        • Chen Y.B.
        • et al.
        B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
        Am J Surg Pathol. 2010; 34: 327-340
        • Green T.M.
        • Young K.H.
        • Visco C.
        • et al.
        Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
        J Clin Oncol. 2012; 30: 3460-3467
        • Harrington A.M.
        • Olteanu H.
        • Kroft S.H.
        • et al.
        The unique immunophenotype of double-hit lymphomas.
        Am J Clin Pathol. 2011; 135: 649-650
        • Wu D.
        • Wood B.L.
        • Dorer R.
        • et al.
        “Double-Hit” mature B-cell lymphomas show a common immunophenotype by flow cytometry that includes decreased CD20 expression.
        Am J Clin Pathol. 2010; 134: 258-265
        • Roth C.G.
        • Gillespie-Twardy A.
        • Marks S.
        • et al.
        Flow cytometric evaluation of double/triple hit lymphoma.
        Oncol Res. 2016; 23: 137-146
        • Dworzak M.N.
        • Buldini B.
        • Gaipa G.
        • et al.
        AIEOP-BFM consensus guidelines 2016 for flow cytometric immunophenotyping of pediatric acute lymphoblastic leukemia.
        Cytometry B Clin Cytom. 2017; ([Epub ahead of print])
        • Sedek L.
        • Bulsa J.
        • Sonsala A.
        • et al.
        The immunophenotypes of blast cells in B-cell precursor acute lymphoblastic leukemia: how different are they from their normal counterparts?.
        Cytometry B Clin Cytom. 2014; 86: 329-339
        • Kroft S.H.
        • Karandikar N.J.
        Flow cytometry in the diagnosis of acute leukemias and myelodysplastic/myeloproliferative disorders.
        in: Keren D.F. McCoy J.P. Carey J.L. Flow cytometry in clinical diagnosis. ASCP Press, Chicago2007: 151-198
        • Seegmiller A.C.
        • Kroft S.H.
        • Karandikar N.J.
        • et al.
        Characterization of immunophenotypic aberrancies in 200 cases of B acute lymphoblastic leukemia.
        Am J Clin Pathol. 2009; 132: 940-949
        • Chen W.
        • Karandikar N.J.
        • McKenna R.W.
        • et al.
        Stability of leukemia-associated immunophenotypes in precursor B-lymphoblastic leukemia/lymphoma: a single institution experience.
        Am J Clin Pathol. 2007; 127: 1-8
        • Borowitz M.J.
        • Pullen D.J.
        • Winick N.
        • et al.
        Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: implications for residual disease detection: a report from the children's oncology group.
        Cytometry B Clin Cytom. 2005; 68: 18-24
        • Gaipa G.
        • Basso G.
        • Maglia O.
        • et al.
        Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection.
        Leukemia. 2005; 19: 49-56
        • McKenna R.W.
        • Washington L.T.
        • Aquino D.B.
        • et al.
        Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry.
        Blood. 2001; 98: 2498-2507
        • McKenna R.W.
        • Asplund S.L.
        • Kroft S.H.
        Immunophenoytpic analysis of hematogones (B-lymphocyte precursors) and neoplastic lymphoblasts by 4-color flow cytometry.
        Leuk Lymphoma. 2004; 45: 277-285
        • Hassanein N.M.
        • Alcancia F.
        • Perkinson K.R.
        • et al.
        Distinct expression patterns of CD123 and CD34 on normal bone marrow B-cell precursors (“hematogones”) and B lymphoblastic leukemia blasts.
        Am J Clin Pathol. 2009; 132: 573-580
        • Hartung L.
        • Bahler D.W.
        Flow cytometric analysis of BCL-2 can distinguish small numbers of acute lymphoblastic leukaemia cells from B-cell precursors.
        Br J Haematol. 2004; 127: 50-58
        • Lee R.V.
        • Braylan R.C.
        • Rimsza L.M.
        CD58 expression decreases as nonmalignant B cells mature in bone marrow and is frequently overexpressed in adult and pediatric precursor B-cell acute lymphoblastic leukemia.
        Am J Clin Pathol. 2005; 123: 119-124
        • Muzzafar T.
        • Medeiros L.J.
        • Wang S.A.
        • et al.
        Aberrant underexpression of CD81 in precursor B-cell acute lymphoblastic leukemia: utility in detection of minimal residual disease by flow cytometry.
        Am J Clin Pathol. 2009; 132: 692-698
        • Hrusak O.
        • Porwit-MacDonald A.
        Antigen expression patterns reflecting genotype of acute leukemias.
        Leukemia. 2002; 16: 1233-1258
        • Djokic M.
        • Bjorklund E.
        • Blennow E.
        • et al.
        Overexpression of CD123 correlates with the hyperdiploid genotype in acute lymphoblastic leukemia.
        Haematologica. 2009; 94: 1016-1019
        • Pui C.H.
        • Rubnitz J.E.
        • Hancock M.L.
        • et al.
        Reappraisal of the clinical and biologic significance of myeloid- associated antigen expression in childhood acute lymphoblastic leukemia.
        J Clin Oncol. 1998; 16: 3768-3773
        • Mancini M.
        • Scappaticci D.
        • Cimino G.
        • et al.
        A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol.
        Blood. 2005; 105: 3434-3441
        • Borowitz M.J.
        • Rubnitz J.
        • Nash M.
        • et al.
        Surface antigen phenotype can predict TEL-AML1 rearrangement in childhood B-precursor ALL: a Pediatric Oncology Group study.
        Leukemia. 1998; 12: 1764-1770
        • Kost C.B.
        • Holden J.T.
        • Mann K.P.
        Marginal zone B-cell lymphoma: a retrospective immunophenotypic analysis.
        Cytometry B Clin Cytom. 2008; 74: 282-286
        • Carlile B.
        • McKenna R.W.
        • Kroft S.H.
        Lymphoplasmacytoid lymphoma: an immunophenotypic re-evaluation.
        Mod Pathol. 2001; 14 ([abstract]): 157A
        • Garcia D.P.
        • Rooney M.T.
        • Ahmad E.
        • et al.
        Diagnostic usefulness of CD23 and FMC-7 antigen expression patterns in B-cell lymphoma classification.
        Am J Clin Pathol. 2001; 115: 258-265
        • Berger F.
        • Felman P.
        • Thieblemont C.
        • et al.
        Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients.
        Blood. 2000; 95: 1950-1956
        • Matutes E.
        • Morilla R.
        • Owusu-Ankomah K.
        • et al.
        The immunophenotype of splenic lymphoma with villous lymphocytes and its relevance to the differential diagnosis with other B-cell disorders.
        Blood. 1994; 83: 1558-1562
        • Delgado J.
        • Matutes E.
        • Morilla A.M.
        • et al.
        Diagnostic significance of CD20 and FMC7 expression in B-cell disorders.
        Am J Clin Pathol. 2003; 120: 754-759
        • Rathke S.K.
        • Chang J.C.
        • Harrington A.M.
        • et al.
        The immunophenotype of prolymphocytoid transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) revisited.
        Mod Pathol. 2013; 26: 356A-357A
        • Tefferi A.
        • Bartholmai B.J.
        • Witzig T.E.
        • et al.
        Heterogeneity and clinical relevance of the intensity of CD20 and immunoglobulin light-chain expression in B-cell chronic lymphocytic leukemia.
        Am J Clin Pathol. 1996; 106: 457-461
        • Monaghan S.A.
        • Peterson L.C.
        • James C.
        • et al.
        Pan B-cell markers are not redundant in analysis of chronic lymphocytic leukemia (CLL).
        Cytometry B Clin Cytom. 2003; 56: 30-42
        • Schlette E.
        • Medeiros L.J.
        • Keating M.
        • et al.
        CD79b expression in chronic lymphocytic leukemia. Association with trisomy 12 and atypical immunophenotype.
        Arch Pathol Lab Med. 2003; 127: 561-566